Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

The fund aims to build a portfolio of 20-25 companies that address gaps in services and products across pharmaceuticals, ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Good news for the sector came January 23 when global pharmaceutical giant AstraZeneca plc announced an eye-popping $820 ...

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

A group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency ...

The portfolio will comprise 20-25 B2B startups spanning Pre-seed to Series A stages, addressing innovation gaps in areas such as pharmaceuticals, biotechnology, medical technology, specialty chemicals ...